Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Operator Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Confere ...

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -137.50%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.07, delivering a surprise of -75%.Over the last four quarters, the company has not been ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus Reports Third Quarter 2024 Results • Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% • Received Approval for Estyme Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 • Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and L ...

Evolus, Inc. (NASDAQ:EOLS) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Nareg Sagherian - Vice President and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Rui Avelar - Chief Medical Officer and Head of R&D Conference Call Participants Jack Padovano - Stifel Navann Ty - BNP Serge Belanger - Needham & Company Operator Good afternoon, everyone and thank you for standing by. Welcome to Evolus' Second Quart ...

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -75%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.13, delivering a surprise of -85.71%. Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance • Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-OverYear Growth of 34% at the Top End • Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Quarter of Profitability with Positive Non-GAAP Operating Income of $1.1 Million for Q2 2024 • Premarket Approval (PMA) Application Submitted to the U ...

Evolus, Inc. (EOLS) has announced favorable results from its pivotal U.S. nasolabial fold (NLF) study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company's strategic expansion within the aesthetic device market. These promising results bolster the company's upcoming Premarket Approval Application ("PMA") for the U.S. launch of Evolus's dermal filler lines. Evolus plans to submit the PMA applications for Evol ...

Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head, Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - Leerink Navann Ty - BNP Paribas Uy Ear - Mizuho Securities Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon everyone and thank ...